The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer.

The metastasis is one of the greatest challenges for successful cancer therapy. Herein, we report a lipid-coated nanodiamond (ND) system loading water-insoluble sorafenib (SND) to improve the bioavailability and efficacy on suppression of cancer metastasis. SND was homogenous nanoassemblies with the mean diameter of 127.6 ± 12.9 nm. Compared with the drug suspension, the sorafenib concentration in gastrointestinal (GI) tract and major organs was significantly increased by SND. Moreover, the oral bioavailability of sorafenib was greatly improved 7.64-fold by SND. However, the ND in SND could not be absorbed into the mucus of GI tract or distributed into major organs after oral administration. Furthermore, the sorafenib concentration in tumor tissue was markedly improved 14.95 folds by SND, and SND demonstrated an efficient and impressive tumor growth inhibition effect in tumor xenograft models. In particular, the metastasis of gastric cancer to distant organs of liver and kidney was remarkably suppressed by SND, which was verified by the detection of macroscopic metastatic nodules, histological examination and immunofluorescence measurements. Thereby, the lipid-coated ND could be a promising drug delivery platform for improving the oral bioavailability of lipophilic drugs and treatment of cancer metastasis.

[1]  S. Nagini,et al.  Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. , 2012, World journal of gastrointestinal oncology.

[2]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[3]  Hak Soo Choi,et al.  Design considerations for tumour-targeted nanoparticles. , 2010, Nature nanotechnology.

[4]  Antonios Kontsos,et al.  Mechanical properties and biomineralization of multifunctional nanodiamond-PLLA composites for bone tissue engineering. , 2012, Biomaterials.

[5]  Juewen Liu,et al.  Nanodiamond decorated liposomes as highly biocompatible delivery vehicles and a comparison with carbon nanotubes and graphene oxide. , 2013, Nanoscale.

[6]  Vesa-Pekka Lehto,et al.  Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. , 2010, ACS nano.

[7]  D. Pang,et al.  Quantum-dots based simultaneous detection of multiple biomarkers of tumor stromal features to predict clinical outcomes in gastric cancer. , 2012, Biomaterials.

[8]  Yaping Li,et al.  A self-assembled nanocarrier loading teniposide improves the oral delivery and drug concentration in tumor. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[9]  A. Goga,et al.  Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment , 2011, Science Translational Medicine.

[10]  R. D'Amato,et al.  An orally delivered small-molecule formulation with antiangiogenic and anticancer activity , 2008, Nature Biotechnology.

[11]  Kuang-Kai Liu,et al.  Endocytic carboxylated nanodiamond for the labeling and tracking of cell division and differentiation in cancer and stem cells. , 2009, Biomaterials.

[12]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[13]  T. Yau,et al.  Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? , 2012, The oncologist.

[14]  Huan-Cheng Chang,et al.  The long-term stability and biocompatibility of fluorescent nanodiamond as an in vivo contrast agent. , 2012, Biomaterials.

[15]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[16]  Yury Gogotsi,et al.  The properties and applications of nanodiamonds. , 2011, Nature nanotechnology.

[17]  J. Maurel,et al.  Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study , 2013, Investigational New Drugs.

[18]  Yan Peng,et al.  Nanodiamonds as intracellular transporters of chemotherapeutic drug. , 2010, Biomaterials.

[19]  Kai Yang,et al.  In vivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration. , 2013, Biomaterials.

[20]  Dean Ho,et al.  Multimodal Nanodiamond Drug Delivery Carriers for Selective Targeting, Imaging, and Enhanced Chemotherapeutic Efficacy , 2011, Advanced materials.

[21]  Fang Gao,et al.  Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[22]  C. Porter,et al.  Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.

[23]  Haijun Yu,et al.  Nanodiamonds-mediated doxorubicin nuclear delivery to inhibit lung metastasis of breast cancer. , 2013, Biomaterials.

[24]  Chunjie Zhao,et al.  Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[25]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[26]  Chunhai Fan,et al.  The Biocompatibility of Nanodiamonds and Their Application in Drug Delivery Systems , 2012, Theranostics.

[27]  Jeffrey N. Myers,et al.  Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice , 2007, Molecular Cancer Therapeutics.

[28]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[29]  Deborah Pareto,et al.  Biodistribution of amino-functionalized diamond nanoparticles. In vivo studies based on 18F radionuclide emission. , 2011, ACS nano.

[30]  L. Gianotti,et al.  Surgical treatment of liver metastases of gastric cancer: state of the art , 2012, World Journal of Surgical Oncology.

[31]  Daniel A. Heller,et al.  Treating metastatic cancer with nanotechnology , 2011, Nature Reviews Cancer.

[32]  G. Krejs,et al.  Gastric Cancer: Epidemiology and Risk Factors , 2010, Digestive Diseases.

[33]  Holger Gerhardt,et al.  Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.

[34]  Tsung-Yuan Hsu,et al.  Fluorescent nanodiamond as a probe for the intercellular transport of proteins in vivo. , 2013, Biomaterials.

[35]  U. Fuhr,et al.  Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.

[36]  Laura M Ensign,et al.  Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. , 2012, Advanced drug delivery reviews.

[37]  M. Sawyer,et al.  Metastatic gastric cancer – focus on targeted therapies , 2012, Biologics : targets & therapy.

[38]  Dean Ho,et al.  Diamond‐Lipid Hybrids Enhance Chemotherapeutic Tolerance and Mediate Tumor Regression , 2013, Advanced materials.

[39]  Houjin Huang,et al.  Nanodiamond-insulin complexes as pH-dependent protein delivery vehicles. , 2009, Biomaterials.

[40]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2007, Nature Reviews Drug Discovery.

[41]  P. Steeg Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.